EUVIMEDScopri EUVIMED
Crossref

A retrospective study to investigate the efficacy and safety of granulocyte and monocyte adsorptive apheresis in patients with primary sclerosing cholangitis with ulcerative colitis

Ayumi Ito, Shun Murasugi iD, Maria Yonezawa, Teppei Omori, Shinichi Nakamura, Katsutoshi Tokushige

Journal of Clinical Apheresis · 2024

DOI: 10.1002/jca.22099 ↗

At a glance

Journal article in Journal of Clinical Apheresis, 2024. Written by Ayumi Ito and 5 co-authors. Institution: Department of Gastroenterology, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan. Major MEDLINE topics: Colitis, Ulcerative, Cholangitis, Sclerosing, Blood Component Removal. 29 references.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background and Aims Primary sclerosing cholangitis has a poor prognosis and can be accompanied by ulcerative colitis. Infection control is essential, so immunosuppressive drugs should ideally be preferably. Granulocyte and monocyte adsorptive apheresis does not suppress the immune system and is used to treat ulcerative colitis. Therefore, this study investigated the efficacy and safety of granulocyte and monocyte adsorptive apheresis in patients with primary sclerosing cholangitis and ulcerative colitis.

Methods

We retrospectively evaluated data from patients with primary sclerosing cholangitis with ulcerative colitis who visited our hospital from April 2000 to December 2022 and underwent granulocyte and monocyte adsorptive apheresis (n = 10, number of treatment cycles = 15). Study endpoints were remission induction rate and safety, assessed as changes in liver functions and adverse events.

Results

Seven of the 10 patients were male. The median (min‐max) age was 23 (18‐77) years. The most common disease type was right‐dominant pancolitis. Remission occurred after 86.6% of cycles (13/15). Serum alkaline phosphatase and Aspartate transaminase were significantly lower after treatment ( P = .0124, P = .002), and no negative effects on liver function were seen. The only adverse events were headache (n = 1) and decreased blood pressure (n = 1).

Conclusions

Granulocyte and monocyte adsorptive apheresis has high efficacy for intestinal lesions and improves alkaline phosphatase and aspartate transaminase levels (high levels are a poor prognosis factor). It appears to be a treatment option in patients with primary sclerosing cholangitis associated with ulcerative colitis.

Subjects

MeSH terms (MEDLINE)

Colitis, UlcerativeCholangitis, SclerosingBlood Component RemovalHumansMaleYoung AdultAdultMiddle AgedAgedFemaleMonocytesRetrospective StudiesLeukapheresisAlkaline PhosphataseTreatment OutcomeGranulocytesAspartate Aminotransferases

Author keywords

monocyte adsorptive apheresisprimary sclerosing cholangitisulcerative colitis

Substances

Alkaline PhosphataseAspartate Aminotransferases

Authors and institutions

  • Department of Gastroenterology, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan.

ORCID profiles: Shun Murasugi

Cite

APA

Ito, A., Murasugi, S., Yonezawa, M., Omori, T., Nakamura, S., & Tokushige, K. (2024). A retrospective study to investigate the efficacy and safety of granulocyte and monocyte adsorptive apheresis in patients with primary sclerosing cholangitis with ulcerative colitis. Journal of Clinical Apheresis. https://doi.org/10.1002/jca.22099

Vancouver

Ito A, Murasugi S, Yonezawa M, Omori T, Nakamura S, Tokushige K. A retrospective study to investigate the efficacy and safety of granulocyte and monocyte adsorptive apheresis in patients with primary sclerosing cholangitis with ulcerative colitis. Journal of Clinical Apheresis. 2024. doi:10.1002/jca.22099

BibTeX
@article{Ito2024,
  author = {Ito, Ayumi and Murasugi, Shun and Yonezawa, Maria and Omori, Teppei and Nakamura, Shinichi and Tokushige, Katsutoshi},
  title = {A retrospective study to investigate the efficacy and safety of granulocyte and monocyte adsorptive apheresis in patients with primary sclerosing cholangitis with ulcerative colitis},
  journal = {Journal of Clinical Apheresis},
  year = {2024},
  doi = {10.1002/jca.22099}
}
Start for free →